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Abstract
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the end point of a broad range of chronic kidney diseases and characterized with decreasing
number of functionally active nephrons. Pathophysiological CKI is characterized by decreased
glomerular  filtration,  which  leads  to  accumulation  of  life-threatening  toxic  metabolites.
Hemodialysis  is  the main therapeutic  measure aimed to prolong patient’s  life  until  kidney
transplant is available. The goal of this study is to analyze serum level of 21 cytokines in CKI.
We have found that the serum level of several (IL-2Rα, IL-3, IL-12 (p40), IL-16, IL-18, HGF, MIF,
CSF-1, MCP-3, CXCL12, SCF, IFN-α2, LIF, β-NGF, and CXCL1) cytokines and chemokines was
upregulated in CKI without hemodialysis as compared to controls (p = 0.005). Interestingly,
serum cytokines were also upregulated in serum of CKI patients who received hemodialysis.
Upregulated cytokines are associated with inflammation and activation of Th1 lymphocytes. We
suggest that hemodialysis has limited effect on serum cytokine levels. It could be concluded
that therapeutic effect of hemodialysis is not associated with removal of inflammatory cytokines
from circulation. Further studies will help better define the underlying cause of an increased
inflammation in CKI and identify the laboratory criteria for anti-inflammatory therapy.
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